2026-06-14T05:05:08Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/201602024-11-28T19:34:21Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Oaknin, A author Rubio, M. J author Redondo, A author De Juan, A author Banuelos, J. F. Cueva author Gil-Martin, M author Ortega, E author Garcia-Arias, A author Gonzalez-Martin, A author Bover Barceló, Isabel 2024-07-04T12:56:34Z 2024-07-04T12:56:34Z 2015-12 Oaknin A, Rubio MJ, Redondo A, De Juan A, Cueva Banuelos JF, Gil-Martin M, et al. SEOM guidelines for cervical cancer. Clin Transl Oncol. 2015 Dec;17(12):1036-42. Epub 2015 Dec 9. 10.1007/s12094-015-1452-2 1699-3055 1699-048X Clinical & Translational Oncology http://hdl.handle.net/20.500.13003/10590 26650487 L607222940 2-s2.0-84952872029 http://hdl.handle.net/20.500.12105/20160 368517900014 Cervical cancer (CC) is the second most common cancer worldwide, strongly linked to high-risk human papilloma virus infection. Although screening programs have led to a relevant reduction in the incidence and mortality due to CC in developed countries, it is still an important cause of mortality in undeveloped countries. Clinical stage is still the most relevant prognostic factor. In early stages, the primary treatment is surgery or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. In the setting of recurrent or metastatic CC, for the first time ever, the combination of chemotherapy plus bevacizumab prolongs the overall survival beyond 12 months. Therefore, this regimen is considered by most of the oncologist a new standard of care for metastatic/recurrent CC. eng Cervical cancer Human papilloma virus Clinical stage SEOM guidelines for cervical cancer research article